Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson's disease.
Journal
Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041
Informations de publication
Date de publication:
11 Mar 2024
11 Mar 2024
Historique:
received:
18
01
2024
accepted:
12
02
2024
revised:
12
02
2024
medline:
12
3
2024
pubmed:
12
3
2024
entrez:
12
3
2024
Statut:
epublish
Résumé
Parkinson's disease (PD) starts at the molecular and cellular level long before motor symptoms appear, yet there are no early-stage molecular biomarkers for diagnosis, prognosis prediction, or monitoring therapeutic response. This lack of biomarkers greatly impedes patient care and translational research-L-DOPA remains the standard of care more than 50 years after its introduction. Here, we performed a large-scale, multi-tissue, and multi-platform proteomics study to identify new biomarkers for early diagnosis and disease monitoring in PD. We analyzed 4877 cerebrospinal fluid, blood plasma, and urine samples from participants across seven cohorts using three orthogonal proteomics methods: Olink proximity extension assay, SomaScan aptamer precipitation assay, and liquid chromatography-mass spectrometry proteomics. We discovered that hundreds of proteins were upregulated in the CSF, blood, or urine of PD patients, prodromal PD patients with DAT deficit and REM sleep behavior disorder or anosmia, and non-manifesting genetic carriers of LRRK2 and GBA mutations. We nominate multiple novel hits across our analyses as promising markers of early PD, including DOPA decarboxylase (DDC), also known as L-aromatic acid decarboxylase (AADC), sulfatase-modifying factor 1 (SUMF1), dipeptidyl peptidase 2/7 (DPP7), glutamyl aminopeptidase (ENPEP), WAP four-disulfide core domain 2 (WFDC2), and others. DDC, which catalyzes the final step in dopamine synthesis, particularly stands out as a novel hit with a compelling mechanistic link to PD pathogenesis. DDC is consistently upregulated in the CSF and urine of treatment-naïve PD, prodromal PD, and GBA or LRRK2 carrier participants by all three proteomics methods. We show that CSF DDC levels correlate with clinical symptom severity in treatment-naïve PD patients and can be used to accurately diagnose PD and prodromal PD. This suggests that urine and CSF DDC could be a promising diagnostic and prognostic marker with utility in both clinical care and translational research.
Identifiants
pubmed: 38467937
doi: 10.1007/s00401-024-02706-0
pii: 10.1007/s00401-024-02706-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
52Informations de copyright
© 2024. The Author(s).
Références
Assarsson E, Lundberg M, Holmquist G, Björkesten J, Thorsen SB, Ekman D et al (2014) Homogenous 96-Plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9:e95192. https://doi.org/10.1371/journal.pone.0095192
doi: 10.1371/journal.pone.0095192
pubmed: 24755770
pmcid: 3995906
Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211. https://doi.org/10.1016/S0197-4580(02)00065-9
doi: 10.1016/S0197-4580(02)00065-9
pubmed: 12498954
Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis 9:197–210. https://doi.org/10.14283/jpad.2022.30
doi: 10.14283/jpad.2022.30
pubmed: 35542991
del Campo M, Vermunt L, Peeters CFW, Sieben A, Hok-A-Hin YS, Lleó A et al (2023) CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease. Nat Commun 14:5635. https://doi.org/10.1038/s41467-023-41122-y
doi: 10.1038/s41467-023-41122-y
pubmed: 37704597
pmcid: 10499811
Christine CW, Bankiewicz KS, Van Laar AD, Richardson RM, Ravina B, Kells AP et al (2019) Magnetic resonance imaging–guided phase 1 trial of putaminal AADC gene therapy for Parkinson’s disease. Ann Neurol 85:704–714. https://doi.org/10.1002/ana.25450
doi: 10.1002/ana.25450
pubmed: 30802998
pmcid: 6593762
Ciesielska A, Samaranch L, Sebastian WS, Dickson DW, Goldman S, Forsayeth J et al (2017) Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; implications for ongoing AAV2-AADC gene therapy trial. PLoS ONE 12:e0169965. https://doi.org/10.1371/journal.pone.0169965
doi: 10.1371/journal.pone.0169965
pubmed: 28166239
pmcid: 5293261
Consortium TGte (2020) The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369:1318–1330. https://doi.org/10.1126/science.aaz1776
doi: 10.1126/science.aaz1776
Diez-Roux G, Ballabio A (2005) Sulfatases and human disease. Annu Rev Genom Hum Genet 6:355–379. https://doi.org/10.1146/annurev.genom.6.080604.162334
doi: 10.1146/annurev.genom.6.080604.162334
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med 388:9–21. https://doi.org/10.1056/NEJMoa2212948
doi: 10.1056/NEJMoa2212948
pubmed: 36449413
Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M et al (2017) Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement Diagn Assess Dis Monit 8:111–126. https://doi.org/10.1016/j.dadm.2017.04.007
doi: 10.1016/j.dadm.2017.04.007
Gesi M, Soldani P, Giorgi FS, Santinami A, Bonaccorsi I, Fornai F (2000) The role of the locus coeruleus in the development of Parkinson’s disease. Neurosci Biobehav Rev 24:655–668. https://doi.org/10.1016/S0149-7634(00)00028-2
doi: 10.1016/S0149-7634(00)00028-2
pubmed: 10940440
Ghilardi MF, Feigin AS, Battaglia F, Silvestri G, Mattis P, Eidelberg D et al (2007) L-Dopa infusion does not improve explicit sequence learning in Parkinson’s disease. Parkinsonism Relat Disord 13:146–151. https://doi.org/10.1016/j.parkreldis.2006.08.006
doi: 10.1016/j.parkreldis.2006.08.006
pubmed: 17055764
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 23:2129–2170. https://doi.org/10.1002/mds.22340
doi: 10.1002/mds.22340
pubmed: 19025984
Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR et al (2008) Placebo response in Parkinson’s disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 23:690–699. https://doi.org/10.1002/mds.21894
doi: 10.1002/mds.21894
pubmed: 18228568
Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN et al (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 5:e15004. https://doi.org/10.1371/journal.pone.0015004
doi: 10.1371/journal.pone.0015004
pubmed: 21165148
pmcid: 3000457
Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T et al (2007) Brain serotonin transporter binding in non-depressed patients with Parkinson’s disease. Eur J Neurol 14:523–528. https://doi.org/10.1111/j.1468-1331.2007.01727.x
doi: 10.1111/j.1468-1331.2007.01727.x
pubmed: 17437611
Hoffman GE, Roussos P (2021) Dream: powerful differential expression analysis for repeated measures designs. Bioinformatics 37:192–201. https://doi.org/10.1093/bioinformatics/btaa687
doi: 10.1093/bioinformatics/btaa687
pubmed: 32730587
Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB et al (2016) A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87:539–547. https://doi.org/10.1212/WNL.0000000000002923
doi: 10.1212/WNL.0000000000002923
pubmed: 27371494
pmcid: 4970664
Kuznetsova A, Brockhoff PB, Christensen RHB (2017) lmerTest Package: tests in linear mixed effects models. J Stat Softw 82:1–26. https://doi.org/10.18637/jss.v082.i13
doi: 10.18637/jss.v082.i13
Lambeir A-M, Durinx C, Scharpé S, Meester ID (2003) Dipeptidyl-peptidase IV from Bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. https://doi.org/10.1080/713609354
doi: 10.1080/713609354
pubmed: 12892317
Lehallier B, Gate D, Schaum N, Nanasi T, Lee SE, Yousef H et al (2019) Undulating changes in human plasma proteome profiles across the lifespan. Nat Med 25:1843–1850. https://doi.org/10.1038/s41591-019-0673-2
doi: 10.1038/s41591-019-0673-2
pubmed: 31806903
pmcid: 7062043
Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ et al (2010) Effects of expectation on placebo-induced dopamine release in Parkinson Disease. Arch Gen Psychiatry 67:857–865. https://doi.org/10.1001/archgenpsychiatry.2010.88
doi: 10.1001/archgenpsychiatry.2010.88
pubmed: 20679593
Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I et al (2003) SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 18:467–486. https://doi.org/10.1002/mds.10459
doi: 10.1002/mds.10459
pubmed: 12722160
Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27:349–356. https://doi.org/10.1002/mds.24893
doi: 10.1002/mds.24893
pubmed: 22275317
pmcid: 3641655
Maes M-B, Martinet W, Schrijvers DM, Van der Veken P, De Meyer GRY, Augustyns K et al (2006) Dipeptidyl peptidase II and leukocyte cell death. Biochem Pharmacol 72:70–79. https://doi.org/10.1016/j.bcp.2006.04.009
doi: 10.1016/j.bcp.2006.04.009
pubmed: 16725115
Maes M-B, Scharpé S, De Meester I (2007) Dipeptidyl peptidase II (DPPII), a review. Clin Chim Acta 380:31–49. https://doi.org/10.1016/j.cca.2007.01.024
doi: 10.1016/j.cca.2007.01.024
pubmed: 17328877
Malloy C, Ahern M, Lin L, Hoffman DA (2022) Neuronal roles of the multifunctional protein dipeptidyl peptidase-like 6 (DPP6). Int J Mol Sci. https://doi.org/10.3390/ijms23169184
doi: 10.3390/ijms23169184
pubmed: 36012450
pmcid: 9409431
Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C et al (2018) The Parkinson’s progression markers initiative (PPMI)—establishing a PD biomarker cohort. Ann Clin Transl Neurol 5:1460–1477. https://doi.org/10.1002/acn3.644
doi: 10.1002/acn3.644
pubmed: 30564614
pmcid: 6292383
Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T et al (2011) The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 95:629–635. https://doi.org/10.1016/j.pneurobio.2011.09.005
doi: 10.1016/j.pneurobio.2011.09.005
pmcid: 9014725
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc 7:263–269. https://doi.org/10.1016/j.jalz.2011.03.005
doi: 10.1016/j.jalz.2011.03.005
Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC et al (2022) Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 387:1099–1110. https://doi.org/10.1056/NEJMoa2204705
doi: 10.1056/NEJMoa2204705
pubmed: 36129998
Molloy DW, Standish TIM (1997) A guide to the standardized mini-mental state examination. Int Psychogeriatr 9:87–94. https://doi.org/10.1017/S1041610297004754
doi: 10.1017/S1041610297004754
pubmed: 9447431
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
doi: 10.1111/j.1532-5415.2005.53221.x
pubmed: 15817019
Ng B, Varoquaux G, Poline JB, Thirion B, Greicius MD, Poston KL (2017) Distinct alterations in Parkinson’s medication-state and disease-state connectivity. NeuroImage Clin 16:575–585. https://doi.org/10.1016/j.nicl.2017.09.004
doi: 10.1016/j.nicl.2017.09.004
pubmed: 28971008
pmcid: 5608603
Oh HS-H, Rutledge J, Nachun D, Pálovics R, Abiose O, Moran-Losada P et al (2023) Organ aging signatures in the plasma proteome track health and disease. Nature 624:164–172. https://doi.org/10.1038/s41586-023-06802-1
doi: 10.1038/s41586-023-06802-1
pubmed: 38057571
pmcid: 10700136
Orrù CD, Ma TC, Hughson AG, Groveman BR, Srivastava A, Galasko D et al (2020) A rapid α-synuclein seed assay of Parkinson’s disease CSF panel shows high diagnostic accuracy. Ann Clin Transl Neurol 8:374–384. https://doi.org/10.1002/acn3.51280
doi: 10.1002/acn3.51280
pubmed: 33373501
pmcid: 7886040
Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O et al (2019) CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol 18:573–586. https://doi.org/10.1016/S1474-4422(19)30024-9
doi: 10.1016/S1474-4422(19)30024-9
pubmed: 30981640
Paslawski W, Khosousi S, Hertz E, Markaki I, Boxer A, Svenningsson P (2023) Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease. Transl Neurodegener 12:42. https://doi.org/10.1186/s40035-023-00374-w
doi: 10.1186/s40035-023-00374-w
pubmed: 37667404
pmcid: 10476347
Pereira JB, Kumar A, Hall S, Palmqvist S, Stomrud E, Bali D et al (2023) DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nat Aging 3:1201–1209. https://doi.org/10.1038/s43587-023-00478-y
doi: 10.1038/s43587-023-00478-y
pubmed: 37723208
pmcid: 10570139
Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183–194. https://doi.org/10.1111/j.1365-2796.2004.01388.x
doi: 10.1111/j.1365-2796.2004.01388.x
pubmed: 15324362
Pham CTN, Ley TJ (1999) Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci 96:8627–8632. https://doi.org/10.1073/pnas.96.15.8627
doi: 10.1073/pnas.96.15.8627
pubmed: 10411926
pmcid: 17567
Poewe W (2009) Treatments for Parkinson disease—past achievements and current clinical needs. Neurology 72:S65–S73. https://doi.org/10.1212/WNL.0b013e31819908ce
doi: 10.1212/WNL.0b013e31819908ce
pubmed: 19221317
Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A, Querejeta-Coma A et al (2022) Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 145:584–595. https://doi.org/10.1093/brain/awab431
doi: 10.1093/brain/awab431
pubmed: 34894214
Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM-Y et al (2013) Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol 74:119–127. https://doi.org/10.1002/ana.23872
doi: 10.1002/ana.23872
pubmed: 23447138
pmcid: 3773265
Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J et al (2017) Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease. Brain 140:3191–3203. https://doi.org/10.1093/brain/awx285
doi: 10.1093/brain/awx285
pubmed: 29140481
pmcid: 5841393
Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C et al (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform 12:77
doi: 10.1186/1471-2105-12-77
Rossi M, Baiardi S, Teunissen CE, Quadalti C, van de Beek M, Mammana A et al (2021) Diagnostic value of the CSF α-synuclein real-time quaking-induced conversion assay at the prodromal MCI stage of dementia with Lewy bodies. Neurology 97:e930–e940. https://doi.org/10.1212/WNL.0000000000012438
doi: 10.1212/WNL.0000000000012438
pubmed: 34210822
pmcid: 8408510
Russo MJ, Orru CD, Concha-Marambio L, Giaisi S, Groveman BR, Farris CM et al (2021) High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease. Acta Neuropathol Commun 9:179. https://doi.org/10.1186/s40478-021-01282-8
doi: 10.1186/s40478-021-01282-8
pubmed: 34742348
pmcid: 8572469
Rutledge J, Lehallier B, Zarifkar P, Losada PM, Ryman S, Yutsis M et al (2022) Aromatic L-amino acid decarboxylase is a novel fluid biomarker of Parkinson’s disease. 2022.11.09.22282149
Sabourdy F, Mourey L, Le Trionnaire E, Bednarek N, Caillaud C, Chaix Y et al (2015) Natural disease history and characterisation of SUMF1 molecular defects in ten unrelated patients with multiple sulfatase deficiency. Orphanet J Rare Dis 10:31. https://doi.org/10.1186/s13023-015-0244-7
doi: 10.1186/s13023-015-0244-7
pubmed: 25885655
pmcid: 4375846
Sánchez-Pernaute R, Harvey-White J, Cunningham J, Bankiewicz KS (2001) Functional effect of adeno-associated virus mediated gene transfer of aromatic l-amino acid decarboxylase into the striatum of 6-OHDA-Lesioned Rats. Mol Ther 4:324–330. https://doi.org/10.1006/mthe.2001.0466
doi: 10.1006/mthe.2001.0466
pubmed: 11592835
Schneider SA, Alcalay RN (2017) Neuropathology of genetic synucleinopathies with Parkinsonism—review of the literature. Mov Disord Off J Mov Disord Soc 32:1504–1523. https://doi.org/10.1002/mds.27193
doi: 10.1002/mds.27193
Shachar T, Bianco CL, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH (2011) Lysosomal storage disorders and Parkinson’s disease: Gaucher disease and beyond. Mov Disord 26:1593–1604. https://doi.org/10.1002/mds.23774
doi: 10.1002/mds.23774
pubmed: 21618611
Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65:403–413. https://doi.org/10.1002/ana.21610
doi: 10.1002/ana.21610
pubmed: 19296504
pmcid: 2696350
Siderowf A, Concha-Marambio L, Lafontant D-E, Farris CM, Ma Y, Urenia PA et al (2023) Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol 22:407–417. https://doi.org/10.1016/S1474-4422(23)00109-6
doi: 10.1016/S1474-4422(23)00109-6
pubmed: 37059509
pmcid: 10627170
Sieber B-A, Landis S, Koroshetz W, Bateman R, Siderowf A, Galpern WR et al (2014) Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson’s Disease 2014 conference. Ann Neurol 76:469–472. https://doi.org/10.1002/ana.24261
doi: 10.1002/ana.24261
pubmed: 25164235
pmcid: 5736367
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330:512–527. https://doi.org/10.1001/jama.2023.13239
doi: 10.1001/jama.2023.13239
pubmed: 37459141
pmcid: 10352931
Simuni T, Chahine L, Poston K, Brumm M, Buracchio T, Campbell M et al (2023) Biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research
SomaLogic (2020) SomaScan® v4 data standardization
SomaLogic SOMAscan® v4 data standardization and file specification technical note
SomaLogic technical specification: adaptive normalization using maximum likelihood
Sonnen JA, Montine KS, Quinn JF, Kaye JA, Breitner JCS, Montine TJ (2008) Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol 7:704–714. https://doi.org/10.1016/S1474-4422(08)70162-5
doi: 10.1016/S1474-4422(08)70162-5
pubmed: 18635019
pmcid: 2710375
Su PC, Ma Y, Fukuda M, Mentis MJ, Tseng H-M, Yen R-F et al (2001) Metabolic changes following subthalamotomy for advanced Parkinson’s disease. Ann Neurol 50:514–520. https://doi.org/10.1002/ana.1232
doi: 10.1002/ana.1232
pubmed: 11601502
Tanaka T, Biancotto A, Moaddel R, Moore AZ, Gonzalez-Freire M, Aon MA et al (2018) Plasma proteomic signature of age in healthy humans. Aging Cell 17:e12799. https://doi.org/10.1111/acel.12799
doi: 10.1111/acel.12799
pubmed: 29992704
pmcid: 6156492
Tolosa E, Garrido A, Scholz SW, Poewe W (2021) Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol 20:385–397. https://doi.org/10.1016/S1474-4422(21)00030-2
doi: 10.1016/S1474-4422(21)00030-2
pubmed: 33894193
pmcid: 8185633
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653. https://doi.org/10.1002/mds.23429
doi: 10.1002/mds.23429
pubmed: 21069833
Walker KA, Chen J, Zhang J, Fornage M, Yang Y, Zhou L et al (2021) Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk. Nat Aging 1:473–489. https://doi.org/10.1038/s43587-021-00064-0
doi: 10.1038/s43587-021-00064-0
pubmed: 37118015
pmcid: 10154040
Wei R, Wang J (2018) multiROC: calculating and visualizing ROC and PR curves across multi-class classifications
Williams SA, Kivimaki M, Langenberg C, Hingorani AD, Casas JP, Bouchard C et al (2019) Plasma protein patterns as comprehensive indicators of health. Nat Med 25:1851–1857. https://doi.org/10.1038/s41591-019-0665-2
doi: 10.1038/s41591-019-0665-2
pubmed: 31792462
pmcid: 6922049